Virus and immune drug combo takes on advanced cancers
NCT ID NCT07185243
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 30 times
Summary
This study tests a new treatment for people with advanced solid tumors that have not responded to standard therapies. The treatment combines a modified virus (hV01) that targets and kills cancer cells while boosting the immune system, with an immunotherapy drug (tislelizumab) that helps the immune system attack cancer. The goal is to see if this combination is safe and can shrink tumors. About 24 adults aged 18 to 75 will receive injections directly into their tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Xiamen Humanity Hospital
RECRUITINGXiamen, Fujian, 361000, China
Conditions
Explore the condition pages connected to this study.